3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Neoplasm Metastasis
3
Philadelphia Chromosome
2
Ovarian Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia
2
Sarcoma
1
Recurrence
1
Peritoneal Neoplasms
1
Neoplasm, Residual
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Genital Neoplasms, Female
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Breast Neoplasms
1
Blast Crisis
1
Appendiceal Neoplasms
1
Interventions
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
ruxolitinib
1
ponatinib
1
fludarabine phosphate
1
fludarabine
1
Whole-Body Irradiation
1
Tacrolimus
1
Quality of Life
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Electrocardiography
1
Cyclophosphamide
1
Clinical Laboratory Techniques
1
CPI-0610
1
Busulfan
1
Bone Marrow Transplantation
1
Bone Marrow Examination
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Bone Marrow Diseases
×
nilotinib
×
90 days
×
Clear all
No trials found.